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Abstract 
BACKGROUND: Neuregulin (NRG) 1 plays an important role in the development of various organ systems in 
human. Single nucleotide polymorphisms rs35753505 C/Tof the gene encoding NRG1 evident as allele C and T 
with genotypes of CT, CC, and TT are believed to have an impact on NRG1 levels. 
AIM: To determine the impact of the NRGrs35753505 C/T polymorphisms on NRG1 levels in preterm infants. 
METHODS: A cross-sectional study was conducted from February to December 2018, whereas 48 eligible 
preterm infants with a gestational age of 32- < 37 weeks were enrolled. An umbilical cord blood specimen was 
collected for determination of NRG1 levels with enzyme-linked immunosorbent assay (ELISA) and NRG1 
polymorphisms with polymerase chain reaction (PCR). Statistical analysis was performed with 95%CI and P value 
of < 0.05 was considered statistically significant. 
RESULTS: Median value of NRG1 levels (174.4 pg/ml) served as a cut off value. NRG 1 polymorphisms 
composed distribution of CC (31%), CT (42%), TT (27%) genotypes and distribution of C and T alleles were 52% 
and 48%. The median NRG1 levels in CC and CT genotypes were significantly lower compared to TT genotype 
(151.1 pg/ml vs 407.2 pg/ml, P = 0.005 and 159.1 pg/ml vs 407.2 pg/ml, P = 0.009). Subjects with C allele had 
significantly lower median NRG1 levels than T allele (151.1 pg/ml vs 407.2 pg/ml, P = 0.002). Subjects with CC 
and CT genotypes had higher risk to develop lower NRG1 levels compared to TT genotype (OR = 8.25, P = 0.016 
and OR = 10.74, P = 0.005, respectively). 
CONCLUSION: Allele C is associated with lower NRG1 levels. Preterm infants with CC and CT genotypes pose a 
higher risk to have lower NRG1 levels. 
 
 
 
 
 
Introduction 
 
The neuregulin (NRG) protein, encoded by 
the neuregulin gene, is a membrane glycoprotein that 
mediates inter-cell signals and plays an important role 
in the growth and development of multiple organ 
systems. It has ligand to thyroxine kinase receptors 
ERBB3 and ERBB4. It concomitantly recruits co-
receptors ERBB1 and ERBB3, which stimulate 
thyroxine phosphorylation and activation of ERBB 
receptors. These isoforms affect the growth and 
differentiation of epithelial cells, glial cells, neurons, 
and muscle cells; induces expression of acetylcholine 
receptors in synaptic vesicles during neuromuscular 
junction generation; stimulates lobuloalveolar budding 
and milk production; stimulates Schwann cell 
proliferation; myocardial development such as 
trabeculation during heart development; neuronal 
migration and regulation of neurotransmitter receptors 
on neurons; play a role in the development of motor 
and sensory neurons [1], [2].
 
Neuregulin 1 is a trophic factor which is a 
subclass of transmembrane GF polypeptide owned by 
family epidermal growth factor (EGF) signalled by 
stimulating ERBB receptor tyrosine kinases. It is a 
family of GF encoded from four different genes of 
NRG-1, NRG-2, NRG-3, and NRG-4, where NRG1 is 
the best characteristic. EGF-like domains are located 
within the membrane-proximal region of the 
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extracellular region, which allows the activation of the 
ErbB receptor tyrosine kinase. NRG1 plays a role in 
stimulating a family of single-transmembrane receptor 
tyrosine kinases called ErbB proteins [3].
 
The last important finding is sequencing and 
the identification of all NRG 1 genes in human that 
have been successfully identified. It has a length of ≈ 
1.4 megabases (≈ 1/2000
th
 of the genome); less than 
0.3% of its length encodes the protein. Due to the 
many alternative splicing and multiple promoters, 
there are at least 15 different NRG isoforms produced 
by a single NRG1 gene. The three important structural 
characteristics that distinguish isoforms in in-vivo 
functions and biological cells are types of EGF-like 
domains (or), N-terminal sequences (type I, II, or 
III) or whether the isoform is directly synthesised as a 
transmembrane or non-membrane protein [4].
 
Single 
nucleotide polymorphisms rs35753505 C/Tof the gene 
encoding NRG1evident as allele C and T with 
genotypes of CT, CC, and TT are believed to have an 
impact on the NRG1 levels. 
 
 
Methods 
 
A cross-sectional study was conducted from 
February to December 2018, whereas 48 preterm 
infants from 5 hospitals in Medan with a gestational 
age of 32- < 37 weeks were enrolled. Infants with 
severe congenital malformation were excluded. 
Umbilical cord blood specimens were collected 
immediately after birth in an EDTA tube for 
determination of NRG1 levels with enzyme-linked 
immunosorbent assay (ELISA). A blood sample was 
centrifuged and frozen at a temperature of -700°C 
until laboratory testing commenced. ELISA was 
performed using the DuoSetHuman NRG1-1/HRG-
. As much as 100 µl sample was added in each well-
containing reagent diluents and incubated for 2 hours. 
Detection antibody (100 µl) was added, and the 
solution was incubated for 2 more hours. Working 
dilution (100 µl) was then added into the solution and 
incubated for 20 minutes. The solution was incubated 
for 20 more minutes after the addition of 100 µl 
substrate solution. At the last step, 50 µl of stop 
solution was added to each well. After being 
centrifuged, the solution’s optical density was 
determined using a microplate reader set to 450 nm. 
Polymerase Chain Reaction was performed 
on 100 of genomic DNA using primer 5’-ACC TAA 
GAT GTC CAA GAG ACA G-3’ forward and 5’-GAC 
TGG AAG CCA TGT ATC TTT ATT GT-3’ reverse 
(Integrated DNA Technologies) and Master mix Go 
Taq Green Master Mix (Promega). Thirty-six 
cycles were performed with 15 minutes denaturation 
at 95°C, 1-minute annealing at 68°C and 1-minute 
extension at 72°C. The difference in NRG1 levels was 
analysed using the Mann-Whitney test. The 
association between polymorphisms and NRG1 levels 
was analysed using the chi-square test. Statistical 
analysis was performed using statistical software at 
95% CI, and a P value of < 0.05 was considered 
significant. This study was approved by the Health 
Research Ethical Committee, Medical School, 
University of Sumatera Utara. 
 
 
Results 
 
The median value of NRG1 levels was 174.4 
pg/ml and served as a cut off value. Neuregulin 1 
polymorphisms rs35753505 C/Tcomposed distribution 
of CC, CT, and TT as many as 31%, 42%, and 27%, 
respectively. Distribution of C and T alleles were 52% 
and 48%. Baseline characteristics of subjects are 
shown in Table 1. 
Table 1: Baseline characteristics of subjects 
Characteristics n (%) 
Mode of delivery, n (%) 
 Normal 
Caesarean section 
 
2 (4.2%) 
48 (95.8%) 
Indication for preterm labor, n (%) 
Medical indication 
Spontaneous 
 
28 (58.3%) 
20 (41.7%) 
Gestational age, week, n (%) 
 32 – < 35 weeks 
 35 – < 37 weeks 
 
16 (33.3%) 
32 (66.7%) 
Gender, n (%) 
Male 
Female 
 
25 (52.1%) 
23 (47.9%) 
Birth weight, gram, n (%) 
< 2.500 
≥ 2.500 
 
27 (56.3%) 
21 (43.8%) 
 
Mann-Whitney test was used to determine the 
differences in serum NRG1 levels between genotypes 
and alleles of neuregulin rs35753505 C/T 
polymorphisms. The median NRG1 levels in CC and 
CT genotypes were significantly lower compared to 
TT genotype (151.1 pg/ml vs 407.2 pg/ml, P = 0.005 
and 159.1 pg/ml vs 407.2 pg/ml, P = 0.009). Subjects 
with C allele had significantly lower median NRG1 
levels than their counterparts (151.1 pg/ml vs 407.2 
pg/ml, P = 0.002) (Figure 1). 
 
Figure 1: The differences in serum NRG1 levels between genotypes 
and alleles of NRG rs35753505 C/T polymorphisms 
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Chi-square test was conducted to determine 
the association between NRG1 rs35753505 C/T 
polymorphisms and NRG1 levels in this study. We 
found a significant association between NRG 
rs35753505 C/T polymorphism with NRG1 levels. 
Subjects with CC and CT genotypes had higher risk to 
have lower NRG1 levels compared to TT genotype 
(OR = 8.25, 95%CI = 1.32-51.26, P = 0.016 and OR = 
10.74, 95% CI = 1.74-59.65, P = 0.005, respectively). 
Subjects with C allele had higher risk to have lower 
NRG1 levels compared to T allele (OR = 2.78, 95% CI 
= 1.21-6.36, P = 0.014) (Table 2). 
Table 2: The association between NRG rs35753505 C/T 
polymorphism with NRG1 levels 
NRG rs35753505 C/T 
polymorphism 
NRG1 levels P OR (95%CI) 
Low 
n (%) 
High 
n (%) 
CC genotype 9 (37.5) 6 (23.0) 0.016
# 
8.25 (1.32 – 51.26) 
CT genotype 13 (54.1) 7 (26.9) 0.005
# 
10.74 (1.74 – 59.65) 
TT genotype 2 (8.3) 13 (50.0)   
C allele 31 (64.6) 19 (39.6) 0.014* 2.78 (1.21 – 6.36) 
T allele 17 (35,4) 29 (60,4)   
*P < 0.05; 
#
significant compared to TT genotype. 
 
 
 
Discussion 
 
The presence of NRG1 has been widely 
studied and has been shown to play a role in fetal 
development. Low NRG1 levels will inhibit surfactant 
formation and affect heart development, nerves, and 
the immune system in premature infants [3], [5], [6], 
[7], [8], [9], [10]. There is no literature that publishes 
the normal cut-off levels of NRG1 in children. Studies 
conducted on the adult population with coronary heart 
disease shows the median NRG1β level in plasma 
and serum in individuals with ischemia of 4100 pg/mL 
and 2400 pg/mL, respectively, whereas for individuals 
without ischemia at 3300 pg/mL and 1600 pg/mL. The 
study also states that NRG1β levels in plasma are 
more accurate than those in serum [11]. Studies 
conducted in clinically healthy populations obtained a 
mean serum NRG1 levels of 217 ng/mL with a range 
of 32 ng/mL to 473 ng/mL [12]. Neuregulin 1 is also 
found in the human cornea; prior studies using the 
PCR showed no difference in the replication of the 
NRG1 coding gene in the cornea and epithelium. This 
demonstrates that NRG1 is produced by relatively 
equal numbers by epithelial and stromal cells [13]. 
The median NRG1 level in this study was 174.4 
pg/mL. Using the median value as a cut off to 
determine high and lower NGR1 levels, an equal 
proportion of subjects with high and lower NRG1 
levels was obtained. This is different from the previous 
study. The previous study has suggested that NRG1 
levels will be lower as more premature the baby is 
[14]. The NRG1 gene, together with the NRG2, 
NRG3, and NRG4 genes, functions to encode the 
NRG1 protein [7]. In these genes, DNA sequences 
variations can occur in the form of SNPs that can 
affect NRG1 production [10]. A study conducted by 
Hoffmann, et al., showed the presence of NRG 
221533 coding gene polymorphism, which resulted in 
77% of infants having at least one C allele [14]. By 
Hardy-Weinberg law, the polymorphism will be passed 
to the next generation in the same proportion if no 
mutation occurred. The impact of these 
polymorphisms will also persist in the next generation 
until other mutations or genetic changes occurred 
[15].
 
In this study, a genetic examination was 
conducted to determine the NRG rs35753505 C/T 
polymorphism. Based on the results of the 
examination, it was found that 42% of subjects had 
CT genotypes, while CC and TT genotypes were 
detected in 31% and 27% of subjects, respectively. 
There was an association between genotypes 
and alleles of the NRG rs35753505 C/T polymorphism 
with NRG1 levels in this study. Subjects with CC and 
CT genotypes had lower NRG1 levels than subjects 
with TT genotype (P = 0.005 and P = 0.009). The 
presence of C allele was associated with a decrease 
in NRG1 levels in the study subjects (P = 0.02). The 
NRG1 rs35753505 polymorphism was associated with 
a decrease in NRG1 levels in this study. Subjects with 
CC and CT genotypes showed a decrease in NRG1 
levels of 8.25 times (P = 0.016) and 10.74 times (P = 
0.005) compared to subjects with TT genotypes. The 
presence of C allele will increase the risk of 
decreasing NRG1 levels by 2.78 times (P = 0.014). 
The previous study reported different results. This is 
different from the results of previous studies where 
neonates, who had C alleles were less often born 
prematurely and had higher NRG levels than 
neonates who had T alleles [14].
 
In conclusion, the median value of NRG1 
levels in the study subjects was 174.4 pg/ml. The 
most frequent NRG rs35753505 C/T polymorphism in 
this study was heterozygous CT genotype (42%). The 
c allele was present in 52% of subjects. The serum 
neuregulin level was lower in subjects with CC and CT 
genotype than subjects with TT genotypes. Subjects 
with C allele showed lower serum NRG1 levels 
compared to subjects with T allele. There was a 
significant relationship between NRG rs35753505 C/T 
polymorphism and NRG1 levels. Subjects with CC 
genotype had a risk of 8.25 times higher having lower 
NRG1 levels than subjects with TT genotype while 
subjects with CT genotype had 10.74 times higher 
risk. The presence of C allele had a risk of 2.78 times 
higher for low NRG1 levels. 
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